Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Status:
Completed
Trial end date:
2018-01-05
Target enrollment:
Participant gender:
Summary
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in
movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized
by chorea (involuntary movements) and a progressive loss of voluntary movement causing a
substantial functional impairment over time. The study will assess the long-term safety of
pridopidine and the treatment effects during long-term, open-label treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Prilenia Teva Branded Pharmaceutical Products, R&D Inc.